Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same author

Opportunities for Human Lung Tissue-Based Studies in Fibrotic ILD Research.

American journal of respiratory and critical care medicine·2026
Same author

Extracorporeal Membrane Oxygenation for Pneumocystis Pneumonia: Outcomes in Patients From the Extracorporeal Life Support Organization.

Critical care explorations·2026
Same author

The impact of obstructive sleep apnea on idiopathic pulmonary fibrosis clinical outcomes.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2026
Same author

The tyrosine kinase receptor EphA2 in alveolar macrophages provides a protective role in host defense against Pneumocystis pneumonia.

The Journal of infectious diseases·2026
Same author

Targeting the DNA damage repair protein RAD51 alters fibroblast metabolism and enhances apoptosis in pulmonary fibrosis.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 14, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Temozolomide-associated organizing pneumonitis.

Fabien Maldonado1, Andrew H Limper, Kaiser G Lim

  • 1Division of Pulmonary and Critical Care Medicine, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. maldonado.fabien@mayo.edu

Mayo Clinic Proceedings
|June 7, 2007
PubMed
Summary

Temozolomide, an oral alkylating agent for glioblastoma, is usually well-tolerated. This report details the first known case of organizing pneumonitis linked to temozolomide treatment.

Related Experiment Videos

Last Updated: Jul 14, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Temozolomide is an oral alkylating agent approved for glioblastoma multiforme treatment.
  • It is known for a generally favorable side effect profile and good tolerability.
  • Pulmonary toxicity requiring treatment cessation is considered rare.

Observation:

  • Mild respiratory symptoms have been previously described with temozolomide use.
  • This case report focuses on a patient experiencing organizing pneumonitis.
  • The condition necessitated discontinuation of the temozolomide therapy.

Findings:

  • This is the first documented instance of organizing pneumonitis associated with temozolomide.
  • The patient's pulmonary toxicity manifested as organizing pneumonitis.
  • The adverse event led to the cessation of temozolomide treatment.

Implications:

  • Highlights a rare but serious potential pulmonary complication of temozolomide.
  • Emphasizes the importance of monitoring respiratory health in patients receiving temozolomide.
  • Suggests a need for further investigation into temozolomide-induced lung injury.